Status:
UNKNOWN
Metabolic Syndrome in Childhood Cancer Survivors
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
5-15 years
Brief Summary
The research is devoted to studying the features of the metabolic syndrome in cancer survivors in childhood is supposed to answer the following questions: * How can metabolic syndrome be diagnosed in...
Detailed Description
Brief Overview: The remarkable progress in developing curative therapy for childhood cancer over the last 4 to 5 decades has increased awareness of the serious cancer treatment-related late effects e...
Eligibility Criteria
Inclusion
- Cancer survivors:
- Treatment with chemotherapy and/or radiation therapy for a primary ALL/NHL diagnosed prior to age 17 years.
- ≤ 15 years of age at the time of enrollment.
- No cytostatic drugs uptake during the study.
Exclusion
- Diagnosis of diabetes mellitus types 1 or 2 types before antitumor therapy
- Active oncological disease
- History of allogeneic hematopoietic cell transplant
- The renouncement of participation from the patient or legally authorized representative
Key Trial Info
Start Date :
November 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 20 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03773718
Start Date
November 20 2018
End Date
December 20 2022
Last Update
December 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow, Russia, 117997